Autologous Peripheral Blood Stem Cell Transplant for Germ Cell Tumors
Summary
RATIONALE: Germ cell tumors (GCT) are highly sensitive to chemotherapy such that even with metastatic disease at diagnosis, many patients can be cured. Patients who fall into the poor risk category or others who relapse can be successfully salvaged with high dose chemotherapy and autologous stem cell transplant (AuSCT). As in other diseases such as myeloma, sequential high dose chemotherapy and AuSCT may improve overall and disease free survival. PURPOSE: Because prior investigations in GCT suggest that a subset of high risk or relapsed patients may be cured with sequential cycles of high dose chemotherapy and AuSCT, we propose investigating how well non-cross resistant conditioning regimens work in treating patients with relapsed or high risk GCT.
Timeline
- Start
- 2006-12-19
- Primary completion
- 2021-03
- Completion
- 2021-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carboplatin | Small molecule | 500 mg/m2 | Intravenous |
| Subject | Etoposide | Small molecule | 600 mg/m2 | Intravenous |
| Subject | Ifosfamide | Small molecule | 2500 mg/m2 | Intravenous |
| Subject | Paclitaxel | Small molecule | 225 mg/m2 | Intravenous |
| Subject | Thiotepa | Other / unclassified | 150 mg/m2 | Intravenous |
| Background | 2-MERCAPTOETHANESULFONIC ACID | Small molecule | 2500 mg/m2 | Intravenous |
| Background | filgrastim | Protein / enzyme biologic | 5 ug/kg | Subcutaneous |